FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018536006> ?p ?o ?g. }

• W2018536006 endingPage "438" @default.
• W2018536006 startingPage "433" @default.
• W2018536006 abstract "Considerable levels of resistance to sulfadoxine-pyrimethamine (SP) have been reported in Plasmodium falciparum in north-eastern Tanzania, and the identification of a suitable antimalarial to replace SP is now a high priority. We conducted a trial in July 2000 to determine the efficacy of proguanil (PG) plus dapsone (DS), compared with that of SP, for the treatment of asymptomatic falciparum infection. A total of 220 children with parasitaemia > or = 2000 per microL completed the study; 112 had received a single dose of SP (dosage calculated for pyrimethamine 1.25 mg/kg and sulfadoxine 25 mg/kg) and 108 had taken PG 10 mg/kg with DS 2.5 mg/kg each day for 3 days. Clearance of asexual parasites at day 7 was 14.3% with SP, but 93.5% with PG-DS. The remarkably high failure rate with SP was not associated with occurrence of leucine substitution at position 164 of the dhfr gene. Both treatment regimens were well tolerated. Compared with available data on another antifolate combination, chlorproguanil-dapsone ('Lapdap'), PG-DS was slightly but significantly inferior in achieving parasite clearance (99.5% versus 93.5%). The estimated cost of a 3-day course of PG-DS treatment for a child weighing 18 kg is US $0.15. With the rising incidence of SP-resistant P. falciparum infection, PG-DS could provide an effective, affordable and already available therapeutic alternative for malaria in East Africa at least until chlorproguanil-dapsone is registered." @default.
• W2018536006 created "2016-06-24" @default.
• W2018536006 creator A5003302916 @default.
• W2018536006 creator A5021018302 @default.
• W2018536006 creator A5028120258 @default.
• W2018536006 creator A5043405150 @default.
• W2018536006 creator A5047705009 @default.
• W2018536006 creator A5074330337 @default.
• W2018536006 creator A5081364566 @default.
• W2018536006 creator A5091845736 @default.
• W2018536006 date "2001-07-01" @default.
• W2018536006 modified "2023-09-26" @default.
• W2018536006 title "A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania" @default.
• W2018536006 cites W1558998716 @default.
• W2018536006 cites W16350362 @default.
• W2018536006 cites W1914219666 @default.
• W2018536006 cites W1964662427 @default.
• W2018536006 cites W1975124091 @default.
• W2018536006 cites W1982522595 @default.
• W2018536006 cites W1989774045 @default.
• W2018536006 cites W2002129908 @default.
• W2018536006 cites W2024129241 @default.
• W2018536006 cites W2025540479 @default.
• W2018536006 cites W2025778096 @default.
• W2018536006 cites W2031154281 @default.
• W2018536006 cites W2036532236 @default.
• W2018536006 cites W2036893696 @default.
• W2018536006 cites W2041235523 @default.
• W2018536006 cites W2048007395 @default.
• W2018536006 cites W2060793519 @default.
• W2018536006 cites W2061212700 @default.
• W2018536006 cites W2061647374 @default.
• W2018536006 cites W2081635625 @default.
• W2018536006 cites W2088401407 @default.
• W2018536006 cites W2089734289 @default.
• W2018536006 cites W2090251268 @default.
• W2018536006 cites W2094805343 @default.
• W2018536006 cites W2097627764 @default.
• W2018536006 cites W2098074409 @default.
• W2018536006 cites W2122539272 @default.
• W2018536006 cites W2168180056 @default.
• W2018536006 cites W2200074758 @default.
• W2018536006 cites W2398374229 @default.
• W2018536006 cites W2405261896 @default.
• W2018536006 cites W2434459097 @default.
• W2018536006 cites W270987812 @default.
• W2018536006 cites W58796253 @default.
• W2018536006 doi "https://doi.org/10.1016/s0035-9203(01)90207-x" @default.
• W2018536006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11579891" @default.
• W2018536006 hasPublicationYear "2001" @default.
• W2018536006 type Work @default.
• W2018536006 sameAs 2018536006 @default.
• W2018536006 citedByCount "37" @default.
• W2018536006 countsByYear W20185360062012 @default.
• W2018536006 countsByYear W20185360062014 @default.
• W2018536006 countsByYear W20185360062016 @default.
• W2018536006 crossrefType "journal-article" @default.
• W2018536006 hasAuthorship W2018536006A5003302916 @default.
• W2018536006 hasAuthorship W2018536006A5021018302 @default.
• W2018536006 hasAuthorship W2018536006A5028120258 @default.
• W2018536006 hasAuthorship W2018536006A5043405150 @default.
• W2018536006 hasAuthorship W2018536006A5047705009 @default.
• W2018536006 hasAuthorship W2018536006A5074330337 @default.
• W2018536006 hasAuthorship W2018536006A5081364566 @default.
• W2018536006 hasAuthorship W2018536006A5091845736 @default.
• W2018536006 hasConcept C203014093 @default.
• W2018536006 hasConcept C2777035104 @default.
• W2018536006 hasConcept C2777234095 @default.
• W2018536006 hasConcept C2777640609 @default.
• W2018536006 hasConcept C2778048844 @default.
• W2018536006 hasConcept C2778301690 @default.
• W2018536006 hasConcept C2778371730 @default.
• W2018536006 hasConcept C2779357621 @default.
• W2018536006 hasConcept C2779636613 @default.
• W2018536006 hasConcept C2780441369 @default.
• W2018536006 hasConcept C39432304 @default.
• W2018536006 hasConcept C71924100 @default.
• W2018536006 hasConcept C86803240 @default.
• W2018536006 hasConcept C91375879 @default.
• W2018536006 hasConcept C98274493 @default.
• W2018536006 hasConceptScore W2018536006C203014093 @default.
• W2018536006 hasConceptScore W2018536006C2777035104 @default.
• W2018536006 hasConceptScore W2018536006C2777234095 @default.
• W2018536006 hasConceptScore W2018536006C2777640609 @default.
• W2018536006 hasConceptScore W2018536006C2778048844 @default.
• W2018536006 hasConceptScore W2018536006C2778301690 @default.
• W2018536006 hasConceptScore W2018536006C2778371730 @default.
• W2018536006 hasConceptScore W2018536006C2779357621 @default.
• W2018536006 hasConceptScore W2018536006C2779636613 @default.
• W2018536006 hasConceptScore W2018536006C2780441369 @default.
• W2018536006 hasConceptScore W2018536006C39432304 @default.
• W2018536006 hasConceptScore W2018536006C71924100 @default.
• W2018536006 hasConceptScore W2018536006C86803240 @default.
• W2018536006 hasConceptScore W2018536006C91375879 @default.
• W2018536006 hasConceptScore W2018536006C98274493 @default.
• W2018536006 hasIssue "4" @default.
• W2018536006 hasLocation W20185360061 @default.
• W2018536006 hasLocation W20185360062 @default.

• next